Department of Gastrointestinal Tumor Surgery, Affiliated Tumor Hospital of Guangzhou Medical College, Guangzhou, China.
PLoS One. 2013;8(2):e56380. doi: 10.1371/journal.pone.0056380. Epub 2013 Feb 11.
CD133 has recently been reported as a marker of cancer stem-like cells in colorectal cancer (CRC). However, its predictive value in CRC still remains controversial. In this study, we aimed to evaluate the association between the expression of CD133 and clinicopathological features and the outcome of CRC patients by performing a meta-analysis.
A comprehensive literature search for relevant studies published up to December 2012 was performed using PubMed, MEDLINE and ISI Web of Science. Only articles in which CD133 antigen was detected in situ localisation by immunohistochemical staining were included. This meta-analysis was done using RevMan 4.2 software.
We found that a total of 15 studies involving 810 CD133-high and 1487 CD133-low patients met the inclusion criteria for the analysis of 5-year overall survival (OS) rate. In a random-effects model, the results showed that CD133-high expression in colorectal cancer was an independent prognostic marker correlating with both OS rate (RR = 0.67, 95%CI 0.54-0.82, P<0.01) and disease free survival (DFS) rate (RR = 0.71, 95%CI 0.52-0.96, P = 0.03). CD133-high expression was also associated with more T3,4 tumor invasion, N positive and vascular invasion cases, corresponding to a risk difference of 1.12 (95%CI 1.01-1.23, P = 0.03), 1.31 (95%CI 1.06-1.63, P = 0.01) and 1.24 (95%CI 1.08-1.41, P<0.01), respectively. However, when types of histology, lymphatic invasion and distant metastasis were considered, CD133 overexpression was not significantly related with these clinicopathological parameters.
Our meta-analysis results suggest that CD133 is an efficient prognostic factor in CRC. Higher CD133 expression is significantly associated with poorer clinical outcome and some clinicopathological factors such as T category, N category and vascular invasion in CRC patients.
CD133 最近被报道为结直肠癌（CRC）中癌症干细胞样细胞的标志物。然而，其在 CRC 中的预测价值仍存在争议。本研究通过荟萃分析旨在评估 CD133 的表达与 CRC 患者的临床病理特征和结局之间的关系。
使用 PubMed、MEDLINE 和 ISI Web of Science 对截至 2012 年 12 月发表的相关研究进行了全面的文献检索。仅纳入通过免疫组织化学染色原位检测 CD133 抗原的文章。该荟萃分析使用 RevMan 4.2 软件进行。
我们发现，共有 15 项研究共纳入 810 例 CD133 高表达和 1487 例 CD133 低表达患者，符合 5 年总生存率（OS）率分析的纳入标准。在随机效应模型中，结果显示 CRC 中 CD133 高表达是与 OS 率（RR=0.67，95%CI 0.54-0.82，P<0.01）和无病生存率（DFS）率（RR=0.71，95%CI 0.52-0.96，P=0.03）相关的独立预后标志物。CD133 高表达还与更多的 T3、4 肿瘤侵袭、N 阳性和血管侵犯病例相关，风险差异分别为 1.12（95%CI 1.01-1.23，P=0.03）、1.31（95%CI 1.06-1.63，P=0.01）和 1.24（95%CI 1.08-1.41，P<0.01）。然而，当考虑组织学类型、淋巴血管侵犯和远处转移时，CD133 过表达与这些临床病理参数无显著相关性。
本荟萃分析结果表明，CD133 是 CRC 中一种有效的预后因素。CD133 高表达与 CRC 患者的临床结局和一些临床病理因素（如 T 分期、N 分期和血管侵犯）显著相关。
